AbbVie shares weekly forecast: recovery holds but faces a stretched setup

Traders Union
All News
Stocks
AbbVie rises 0.21% over the week

Highlights

Shares of AbbVie edged up $0.4 on the week to $264.66, holding above both short-term and long-term moving averages.
Momentum indicators show ongoing buying pressure but with Stochastic RSI in a deeply overbought condition, suggesting possible short-term exhaustion.
AbbVie stock is expected to consolidate between $261.44 and $267.87, with a 71% probability of an increase and key resistance at $269.37.

FDA approvals and new AI partnerships fuel positive flows this week

On September 28, 2026, AbbVie received U.S. FDA approval for Juvmo (tavapadon), a new drug for Parkinson's disease, strengthening its position in movement disorders, according to GuruFocus and CoinCentral. Yahoo Finance, Pulse2, and Crain's Chicago Business also reported a multiyear partnership with Iambic to develop small-molecule drugs in immunology, neuroscience, and oncology using AI-driven discovery platforms. Additional catalysts for ABBV include a recently acquired stake in ADARx Pharmaceuticals during its IPO, providing exposure to RNA interference therapies, and Health Canada approval for a new follicular lymphoma indication for EPKINLY in combination therapy.

Overbought momentum challenges further upside amid weekly consolidation

On the daily chart, momentum is showing a contained move within a narrow range, as reflected in the week’s 2.75% volatility. The MACD points to ongoing buying momentum, while Stochastic RSI is deep in the overbought zone at 89.26, indicating potential exhaustion after recent gains. Nearest support sits at $262.17 and resistance is found at $269.37, with the Ichimoku Kijun also acting as practical support at $258.39. This mix of signals suggests further near-term consolidation with an upward bias, but with overbought readings limiting the likelihood of a sustained breakout.

Directional risk pivots on breakout as consolidation likely next week

In the week ahead, AbbVie stock is expected to trade between $261.44 and $267.87. There is a 71% probability of an increase, and a 29% chance of a decrease. The base case is for continued consolidation within the expected range, anchored by support at $262.17 and resistance at $269.37. A sustained move above $269.37 could trigger a more decisive bullish advance, while a drop below $262.17 would open the way to deeper retracement.

Viktoras Karapetjanc, expert at Traders Union, sees a constructive setup for AbbVie shares near $265 this week, with the bullish structure underpinned by resilient daily momentum. Recent regulatory wins — notably the U.S. FDA approval for Juvmo and a strategic partnership with Iambic in AI-driven drug development — signal strong fundamental drivers, while new exposure to RNA therapies and expanded approvals in oncology further strengthen the company’s positioning. The technical picture shows consolidation within a tight range, with the MACD indicating ongoing buying interest and overbought Stochastic RSI at 89.26 hinting at brief pauses before fresh moves. Key support lies at $262.17, with resistance ahead at $269.37; as long as price holds above these levels, further upward movement remains likely. "I expect continued consolidation with a positive tilt, and if AbbVie stock breaks above $269.37, we could see a stronger rally developing this week."

Previously it was reported that AbbVie maintained a bullish technical structure as regulatory approvals and clinical advancements supported its long-term consolidation. The current setup points to a continued period of consolidation with an upward bias, with $269.37 serving as the key resistance level to monitor for a possible breakout.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.